 |
|
Historic gene therapy trial to treat Alzheimer's disease underway at Georgetown
September 23, 2009Washington, DC -- Researchers in the Memory Disorders Program at Georgetown University Medical Center are now recruiting volunteers for a national gene therapy trial - the first study of its kind for the treatment of patients with dementia due to Alzheimer's disease.
The phase II study examines the safety and possible benefits of CERE-110. CERE-110 contains a gene and is injected during surgery into a part of the brain affected by Alzheimer's disease. The gene will instruct brain cells to produce more of a protein, called Nerve Growth Factor or NGF, which helps nerve cells survive and function properly. The transfer of this gene into the brain is a medical technique called gene therapy.
"Our goal is to stop the progression of Alzheimer's disease," explains R. Scott Turner, MD, PhD, director of Georgetown's Memory Disorders Program. "This is our first study of a gene therapy injected into brain, and thus the trial requires close collaboration with our neurosurgery colleagues at GUMC, in particular Dr. Chris Kalhorn."
Turner says Kalhorn, an associate professor of the department of neurosurgery at Georgetown University Hospital, routinely performs neurosurgical procedures similar to the one being utilized in this study.
About 50 people with Alzheimer's disease will participate in this study at fewer than 10 hospitals nationwide. Only persons with a mild form of Alzheimer's Disease, who are evaluated and deemed competent to consent for themselves, will be permitted to participate in the study. The study requires each patient select a study partner for the length of the study. All patients in the study will undergo surgery to drill two small holes in the skull. Only those patients randomly assigned to receive CERE-110 will have the gene therapy injected into the brain. Those subjects randomized to the placebo group will not have the gene therapy injected.
This study is a phase II, double-blind, placebo-controlled study.
Phase II means the investigational agent has been studied in a small number of patients and this study is being conducted to determine its safety and possible benefits.
Double-blind means that the patients, clinical coordinators and treating physicians will not know if the patient received the investigational agent until the end of the study. Only the neurosurgeon and operating team delivering the gene therapy will know if the patient received the active agent.
Placebo-controlled means that patients will be selected randomly to either receive the active agent or not, but all patients will undergo surgery. This study has been approved by the FDA and the Institutional Review Board at GUMC.
Georgetown University Medical Center
Turner says Kalhorn, an associate professor of the department of neurosurgery at Georgetown University Hospital, routinely performs neurosurgical procedures similar to the one being utilized in this study.
About 50 people with Alzheimer's disease will participate in this study at fewer than 10 hospitals nationwide. Only persons with a mild form of Alzheimer's Disease, who are evaluated and deemed competent to consent for themselves, will be permitted to participate in the study. The study requires each patient select a study partner for the length of the study. All patients in the study will undergo surgery to drill two small holes in the skull. Only those patients randomly assigned to receive CERE-110 will have the gene therapy injected into the brain. Those subjects randomized to the placebo group will not have the gene therapy injected.
This study is a phase II, double-blind, placebo-controlled study.
Phase II means the investigational agent has been studied in a small number of patients and this study is being conducted to determine its safety and possible benefits.
Double-blind means that the patients, clinical coordinators and treating physicians will not know if the patient received the investigational agent until the end of the study. Only the neurosurgeon and operating team delivering the gene therapy will know if the patient received the active agent.
Placebo-controlled means that patients will be selected randomly to either receive the active agent or not, but all patients will undergo surgery. This study has been approved by the FDA and the Institutional Review Board at GUMC.
Georgetown University Medical Center
Gene Therapy Current Events and Gene Therapy News RSSResearch reveals lipids' unexpected role in triggering death of brain cells
The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators.
No-entry zones for AIDS virus
The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.
Cornell researchers identify a weak link in cancer cell armor
The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves.
Treatment to improve degenerating muscle gains strength
A study appearing in Science Translational Medicine puts scientists one step closer to clinical trials to test a gene delivery strategy to improve muscle mass and function in patients with certain degenerative muscle disorders.
Iowa State University researcher discovers key to vital DNA, protein interaction
A researcher at Iowa State University has discovered how a group of proteins from plant pathogenic bacteria interact with DNA in the plant cell, opening up the possibility for what the scientist calls a "cascade of advances."
Scientists successfully reprogram blood cells
Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.
Immune therapy can protect against or treat later lymphoma
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection.
Caltech researchers show efficacy of gene therapy in mouse models of Huntington's disease
Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Toward bold new anti-cancer medicines
Bold new strategies in the battle against cancer may turn forms of the disease that presently are incurable into manageable conditions that can be controlled for long periods of time.
More Gene Therapy Current Events and Gene Therapy News Articles
 |
Gene Therapy: Treating Disease by Repairing Genes (New Biology) by Joseph, Ph.D. Panno (Author) Many diseases are caused by a simple point mutation - they are the result of a single defective gene. Gene therapy is the attempt to replace a defective gene with a good copy or to add a good gene to compensate for the bad. Although this procedure has proven to be extremely hazardous, of all the technologies provided by the new biology, gene therapy holds much potential for curing disease. Dealing with one of the most controversial aspects of the new biology, Gene Therapy explores the development and future of this area of research and explains why it is considered such a promising branch of science. This encyclopedia presents an overview of genetic defects, viruses, and gene therapy in a way that students and general readers will find easy to understand. Comprehensive in scope, this book... |
 |
Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Third Edition by Nancy Smyth Templeton (Editor) Since the publication of the second edition of this book in 2004, gene therapy and cell therapy clinical trials have yielded some remarkable successes and some disappointing failures. Now in its third edition, Gene and Cell Therapy: Therapeutic Mechanisms and Strategies assembles many of the new technical advances in gene delivery, clinical applications, and new approaches to the regulation and modification of gene expression. New Topics Covered in this Edition: Gene and Cell Therapies for Diabetes and Cardiovascular Diseases Clinical Trials Human Embryonic Stem Cells Tissue Engineering Combined with Cell Therapies Novel Polymers Relevant Nanotechnologies SiRNA Therapeutic Strategies Dendrimer Technologies Comprised of... |
 |
Gene Therapy by Mary Colavito (Author), Michael A. Palladino (Author) KEY MESSSAGE: Will gene therapy one day become the ultimate application of genetic technology? Gene Therapy, the newest booklet in the Special Topics in Biology Series, addresses this question by exploring gene therapy as a complex technology for delivering therapeutic genes as a way to treat and cure human genetic diseases. Author Mary Colavito provides an overview of the basic science involved in gene therapy methods and chronicles the history of gene therapy by discussing successful and ongoing gene therapy treatments as well as adverse outcomes in some cases of gene therapy. Also discussed are challenges that must be overcome for gene therapy to become a more reliable and readily accessible approach for treating a multitude of genetic diseases that affect... |
 |
Gene Therapy and Gene Delivery Systems (Advances in Biochemical Engineering / Biotechnology) by David V. Schaffer (Editor), Weichang Zhou (Editor) 1 D.V. Schaffer, W. Zhou: Gene Therapy as Future Human Therapeutics.- 2 J. Heidel, S. Mishra, M.E. Davis: Molecular Conjugates.- 3 M. Manthorpe, P. Hobart, G. Hermanson, M. Ferrari, A. Geall, B. Goff, A. Rolland: Plasmid Vaccines and Therapeutics: From Design to Applications.- 4 S.R. Little, R. Langer: Non-Viral Delivery of Cancer Genetic Vaccines.- 5 J.C. Grieger, R.J. Samulski: Adeno-Associated Virus as a Gene Therapy Vector: Vector Development, Production and Clinical Applications.- 6 J.H. Yu, D.V. Schaffer: Advanced Targeting Strategies for Murine Retroviral and Adeno-Associated Viral Vectors.- 7 N. Loewen, E.M. Poeschla: Lentiviral Vectors.- 8 N.E. Altaras, J.G. Aunins, R.K. Evans, A. Kamen, J.O. Konz, J.J. Wolf: Production and Formulation of Adenovirus Vectors.- |
|
Gene Therapy & Molecular Biology by Intl Soc Gene Therapy Mole Bio | |
 |
Jazz Therapy, Vol. 1: Smile by Gene Bertoncini & Roni Ben-Hur The first in a new series of fundraising CDs produced in association with the Jazz Foundation of America, and the first time these two popular guitarists have recorded together. Liner notes by Ira Gitler. Entire CD was played, recorded, packaged, and is being promoted on a pro-bono basis, raising funds for the Englewood Hospital and Medical Center's Dizzy Gillespie Fund. |
 |
Gene Therapy: Dawn of a New Age in Medicine (NCME Video 653) Also With: Kenneth W. Culver (Primary Contributor), Network For Continuing Medical Education (Primary Contributor) |
 |
Six Years of Gene Therapy Son of Rust (Primary Contributor) |
 |
Immunology of Gene Therapy by Roland W. Herzog (Author) Summarises and reviews the important field of genetic therapy with respect to the latest immunological advances in the lab and clinic Unique treatment of immunology and immunotherapy in gene - approached from a vector and target organ point of view rather than from the perspective a specific diseases Broad appeal - applicable for immunology and genetics / gene therapy, recombinant DNA studies, transplantation, virology, cancer research and tumor research |
 |
Chromosome 11 Gene Therapy Sickle Cell Anemia Photographic Poster Print, 24x32 by Art.com Art.com is the world's largest retailer of art prints, posters, photographs, and framed artwork. With our huge selection of over 400,000 prints, you'll easily find the perfect piece for your home, office, or classroom. Our art is printed on quality paper. When you order framed artwork, the piece is built by our team of in-house professionals. Visit our Amazon store today at www.amazon.com/artdotcom to find Special Offers and search for products based on 'Artist Name' and 'Subject Categories' such as Movie, Music, Vintage, TV, Children, Travel, Kitchen, Museum Art, Animals, Floral, Motivational, and Sports. Art.com is dedicated to providing you with high quality products and service by offering you 100% satisfaction guaranteed. We ship internationally to over 80 countries. Decorate your... |
| © 2009 BrightSurf.com |